Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.60 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 3/20 | 0.43 |
| ▸ | AGXT | P21549 | 2/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2799159 | 0.98 | SLC6A2 (0.59) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL22462571 | 0.90 | SLC6A2 (0.52) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL25343157 | 0.86 | LOXL2 (0.48) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL25343692 | 0.81 | SLC6A2 (0.42) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL25342534 | 0.81 | SLC6A2 (0.61) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL15812042 | 0.80 | LOXL2 (0.48) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL7267223 | 0.80 | LOXL2 (0.43) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL228926 | 0.80 | SLC6A2 (0.67) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL2615503 | 0.80 | ESR1 (0.58) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL72988 | 0.80 | ESR1 (0.58) | SLC6A2HTR2ASLC6A4HRH1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101704756-B | The synthetic method of 1-(4-fluorophenyl)-2-methyl-2-propylamine | 大连九信精细化工有限公司 | 2017-12-05 | — | — | CN | claimed |
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | claimed |
| CN-101704756-A | Synthesis method of 1- (4-fluorophenyl) -2-methyl-2-propylamine | DALIAN KAIFEI FINE CHEMICALS C | 2010-05-12 | — | — | CN | claimed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | claimed |
| EP-1144384-B1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2007-10-31 | — | — | EP | claimed |
| US-7009052-B2 | Sulfonamide derivatives | WARNER LAMBERT COMPANY LLC (US) | 2006-03-07 | — | — | US | claimed |
| US-20050004367-A1 | Sulfonamide derivatives | DU DANIEL Y (US) | 2005-01-06 | — | — | US | claimed |
| US-20040259887-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-12-23 | — | — | US | claimed |
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250049036-A1 | SUBSTITUTED FUSED BICYCLIC PYRIDINE CARBOXAMIDE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | PI INDUSTRIES LTD. (IN) | 2025-02-13 | — | — | US | disclosed |
| EP-4448494-A1 | NOVEL SUBSTITUTED FUSED BICYCLIC PYRIDINE CARBOXAMIDE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | PI Industries Ltd. (IN) | 2024-10-23 | — | — | EP | disclosed |
| US-12059422-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| EP-3715342-B1 | FLUOROSULFONYL-CONTAINING COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHONGHONGXIN INVEST HOLDINGS SHENZHEN CO LTD (CN) | 2024-08-07 | — | — | EP | disclosed |
| US-20240083839-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-03-14 | — | — | US | disclosed |
| US-5621010-A | ANTIHYPERCHOLESTEROLEMIA AND ANTIATHEROSCLEROSIS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| US-5514502-A | STYRENE-MALEIC ANHYDRIDE MODIFIED WITH AMINE | FUJI PHOTO FILM CO., LTD. (JP) | 1996-05-07 | — | — | US | disclosed |
| EP-0625507-A2 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1994-11-23 | — | — | EP | disclosed |
| US-5153327-A | 7-Oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease | E. R. SQUIBB & SONS, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| US-5100889-A | Thromboxane A2 receptor antagonists, thromboxane synthetase inhibitor | E. R. SQUIBB & SONS, INC. (US) | 1992-03-31 | — | — | US | disclosed |
| US-3979514-A | Process for interrupting pregnancy with sulfonamidoaminophene interceptive agents | MEAD JOHNSON & COMPANY (US) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049036-A1 | SUBSTITUTED FUSED BICYCLIC PYRIDINE CARBOXAMIDE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | CBR3, C5, CBR1 | SLC6A2 4827/4885HTR2A 3575/4885SLC6A4 4768/4885 |
| US-20040259887-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | SLC6A2 1393/4885HTR2A 138/4885SLC6A4 1093/4885 |
| US-12059422-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | CCNI, CCNK, CCNA1 | SLC6A2 4508/4885HTR2A 1861/4885SLC6A4 4601/4885 |
| US-20050004367-A1 | Sulfonamide derivatives | AR, SULT2A1, SHBG | SLC6A2 584/4885HTR2A 130/4885SLC6A4 241/4885 |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | SLC6A2 2121/4885HTR2A 550/4885SLC6A4 2157/4885 |
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | SLC6A2 2245/4885HTR2A 253/4885SLC6A4 2051/4885 |
| US-20240083839-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | PRMT8, SIRT1, PRMT3 | SLC6A2 3591/4885HTR2A 2772/4885SLC6A4 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.